JP6266506B2 - Ｈｓｐ９０阻害物質 - Google Patents

Ｈｓｐ９０阻害物質 Download PDF

Info

Publication number
JP6266506B2
JP6266506B2 JP2014503994A JP2014503994A JP6266506B2 JP 6266506 B2 JP6266506 B2 JP 6266506B2 JP 2014503994 A JP2014503994 A JP 2014503994A JP 2014503994 A JP2014503994 A JP 2014503994A JP 6266506 B2 JP6266506 B2 JP 6266506B2
Authority
JP
Japan
Prior art keywords
another embodiment
amino
methyl
pharmaceutically acceptable
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510148A5 (cg-RX-API-DMAC7.html
JP2014510148A (ja
Inventor
ウェイリン スン，
ウェイリン スン，
トニー タルドーン，
トニー タルドーン，
パラブ パテル，
パラブ パテル，
ガブリエラ チオシス，
ガブリエラ チオシス，
Original Assignee
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケッタリング インスティチュート フォー キャンサー リサーチ, スローン − ケッタリング インスティチュート フォー キャンサー リサーチ filed Critical スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Publication of JP2014510148A publication Critical patent/JP2014510148A/ja
Publication of JP2014510148A5 publication Critical patent/JP2014510148A5/ja
Application granted granted Critical
Publication of JP6266506B2 publication Critical patent/JP6266506B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014503994A 2011-04-05 2012-04-05 Ｈｓｐ９０阻害物質 Expired - Fee Related JP6266506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
US61/472,061 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016228549A Division JP2017061540A (ja) 2011-04-05 2016-11-25 Ｈｓｐ９０阻害物質

Publications (3)

Publication Number Publication Date
JP2014510148A JP2014510148A (ja) 2014-04-24
JP2014510148A5 JP2014510148A5 (cg-RX-API-DMAC7.html) 2015-05-21
JP6266506B2 true JP6266506B2 (ja) 2018-01-24

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503994A Expired - Fee Related JP6266506B2 (ja) 2011-04-05 2012-04-05 Ｈｓｐ９０阻害物質

Country Status (11)

Country Link
US (2) US9346808B2 (cg-RX-API-DMAC7.html)
EP (1) EP2694505B1 (cg-RX-API-DMAC7.html)
JP (1) JP6266506B2 (cg-RX-API-DMAC7.html)
KR (1) KR102010222B1 (cg-RX-API-DMAC7.html)
CN (1) CN103582642B (cg-RX-API-DMAC7.html)
AU (1) AU2012240077C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025634A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832530C (cg-RX-API-DMAC7.html)
EA (1) EA201391334A1 (cg-RX-API-DMAC7.html)
MX (1) MX360390B (cg-RX-API-DMAC7.html)
WO (1) WO2012138894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2729806B1 (en) * 2011-07-08 2017-02-22 Sloan-kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
KR102325454B1 (ko) * 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
KR20170052687A (ko) 2014-09-17 2017-05-12 메모리얼 슬로안-케터링 캔서 센터 Ｈｓｐ90-표적화된 염증 및 감염 영상화 및 치료
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2017062520A1 (en) 2015-10-05 2017-04-13 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
CA3068274A1 (en) * 2017-06-23 2018-12-27 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
WO2002100399A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
BR0308056A (pt) 2002-02-28 2004-12-07 Astrazeneca Ab Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2634723A1 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
CA2652263A1 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
BRPI0808301B1 (pt) 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
EP2183221A1 (en) * 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2705579A1 (en) 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
MX2011007612A (es) 2009-01-16 2012-01-20 Curis Inc Aminopiridinas fusionadas para el tratamiento de tumores del cerebro.
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
CN102781520B (zh) * 2009-07-17 2016-06-08 帕夫泰克技术私人有限公司 呼吸器
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения

Also Published As

Publication number Publication date
MX2013011532A (es) 2014-08-22
WO2012138894A1 (en) 2012-10-11
US9346808B2 (en) 2016-05-24
CA2832530A1 (en) 2012-10-11
CN103582642B (zh) 2021-05-11
US9926321B2 (en) 2018-03-27
KR20140062429A (ko) 2014-05-23
WO2012138894A4 (en) 2012-12-06
KR102010222B1 (ko) 2019-08-13
EA201391334A1 (ru) 2014-06-30
AU2012240077A1 (en) 2013-10-31
CA2832530C (en) 2021-02-16
MX360390B (es) 2018-10-31
EP2694505A1 (en) 2014-02-12
AU2012240077B2 (en) 2017-04-20
AU2012240077C1 (en) 2017-08-10
NZ616758A (en) 2016-01-29
JP2014510148A (ja) 2014-04-24
US20140088121A1 (en) 2014-03-27
US20160264577A1 (en) 2016-09-15
EP2694505B1 (en) 2022-04-27
CN103582642A (zh) 2014-02-12
BR112013025634A2 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
JP6266506B2 (ja) Ｈｓｐ９０阻害物質
JP5961683B2 (ja) Ｈｓｐ９０阻害物質
KR20210134738A (ko) Jak 억제제 및 그 제조방법과 의약분야에서의 응용
CA3077267C (en) Fused heteroaryl ring derivatives useful as a2a receptor inhibitor
JP2017061540A (ja) Ｈｓｐ９０阻害物質
HK1194376B (en) Hsp90 inhibitors
HK1194376A (en) Hsp90 inhibitors
NZ616758B2 (en) Hsp90 inhibitors
HK1194375A (en) Hsp90 inhibitors
HK1194375B (en) Hsp90 inhibitors
JP2022538119A (ja) １－（２－（（（（ｔｒａｎｓ）－３－フルオロ－１－（３－フルオロピリジン－２－イル）シクロブチル）メチル）アミノ）ピリミジン－５－イル）－１Ｈ－ピロール－３－カルボキサミドの多形
NZ616890B2 (en) Hsp90 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

R150 Certificate of patent or registration of utility model

Ref document number: 6266506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees